Sensorium Therapeutics

Hope For The 43 Million Americans Who Suffer From Anxiety

About this Event

If you know someone with Social Anxiety Disorder (SAD) – since 43 million Americans suffer from it, there’s a good chance you do – you know how devastating it can be. At its extremes, it prevents people from socializing effectively, going to school, work, or participating in any other day-to day activities. Current medications only work about half the time and have significant side effects including agitation, insomnia, erectile disfunction, and suicidal ideation in younger patients.

Sensorium Therapeutics was founded to help people with SAD and other Central Nervous System (CNS) Diseases that have historically been significantly underfunded and subsequently lack effective treatment options.

Sensorium has built the most comprehensive database of individually annotated natural compounds, their medicinal uses, relevant efficacy, and safety data. The company’s mission is to create novel medicines with a higher probability of clinical and commercial success. Their lead program, SNTX-2643 is a derivative of a natural compound with a long history of human efficacy in safely treating anxiety. The company is completing its IND application and will begin clinical trials in Q1 2025.

In addition to SNTX-2643, Sensorium is advancing other compounds with human data in epilepsy, Alzheimer’s disease, and has identified additional compounds with the potential to address depression, non-opioid pain treatment, obesity, and diabetes.

Video On Demand

– Recorded

January 22

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.